Prospective Coronary Heart Disease Cohort

A Prospective Longitudinal Multi-Omics Cohort of Patients With Coronary Heart Disease Undergoing Coronary Angiography

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05699629

Enrollment

50000

Registered

2023-01-26

Start date

2022-01-21

Completion date

2027-01-21

Last updated

2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease, Myocardial Infarction

Brief summary

To evaluate the biomarkers for the prognosis of coronary heart disease, patients with coronary heart disease will be recruited and followed up for at least 2 years.

Detailed description

Patients with cardiovascular disease undergoing coronary angiography will be recruited and prospectively followed up for the incidence of major adverse cardiovascular events (MACE events), including all-cause mortality, cardiovascular mortality, ischemic stroke, heart failure and rehospitalization. Blood and fecal samples will be collected for further analysis. The basic and clinical information will be collected such as socio-demographic, diet, lifestyle, psychological status and medical history. The biomarkers for the incidence of coronary heart disease and the factors contributing to the poor prognosis of coronary heart disease will be investigated based on multi-omics analysis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Diagnosed as coronary heart disease or with unexplained chest pain needed to undergo coronary angiography. * Healthy subjects undergoing routine physical examination in the physical examination department and willing to sign informed consent will be recruited as control subjects.

Exclusion criteria

* With malignant tumors, infectious diseases and advanced liver diseases. * Won't sign an inform consent.

Design outcomes

Primary

Measure	Time frame	Description
major adverse cardiovascular events	2-year outcome and long-term outcome	all-cause mortality, cardiovascular mortality, ischemic stroke, heart failure and rehospitalization

Countries

China

Contacts

Primary ContactRong Huang, Dr.

huangrong9277@163.com18854125717

Outcome results